Stoke Therapeutics Presents Data from a Combined Interim Analysis of the Phase 1/2a MONARCH and ADMIRAL Studies of ...
December 2, 2022
– Single and multiple doses of STK-001 up to 45mg were well-tolerated – – 55% median reduction from baseline in convulsive se ...Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Program at the American Epilepsy Society 2022 ...
November 29, 2022
– Seven abstracts related to the Company’s work in Dravet syndrome will be presented, including data from a combined interim ...Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
November 14, 2022
– Company announces positive interim data from the ongoing Phase 1/2a clinical studies of STK-001 in children and adolescents ...Stoke Therapeutics to Host Webinar and Conference Call to Present Interim Data from the Phase 1/2a Studies of STK-0 ...
November 10, 2022
BEDFORD, Mass. --(BUSINESS WIRE)--Nov. 10, 2022-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated ...Stoke Therapeutics Enrolls First Patient in a Natural History Study of People Living with Autosomal Dominant Optic ...
August 25, 2022
– ADOA is primarily caused by mutations in the OPA1 gene that result in progressive and irreversible vision loss in both eyes ...Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
August 8, 2022
– In the fourth quarter, the Company plans to announce interim safety, pharmacokinetic (PK), and cerebrospinal fluid (CSF) dr ...Stoke Therapeutics to Present at the 2022 Jefferies Healthcare Conference
June 1, 2022
BEDFORD, Mass. --(BUSINESS WIRE)--Jun. 1, 2022-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated t ...Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
May 10, 2022
– 2H 2022 clinical data readout on track for patients with Dravet syndrome who received multiple doses of STK-001 (30mg) in P ...Stoke Therapeutics Presents New In-Vivo Data That Demonstrated Dose-Related Target Engagement and OPA1 Protein Upre ...
May 2, 2022
– Data presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting support the Company’s work ...Stoke Therapeutics to Present at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meetin ...
April 7, 2022
– New preclinical data support the ongoing preclinical development of STK-002 for the treatment of autosomal dominant optic a ...